This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Arquivo

Are classification criteria for vasculitis useful in clinical practice?

2016-07-13T16:29:04+00:00 2009-11-13|Categories: Arquivo|

Observations and lessons from Colombia Published: 27 February 2009 Journal of Autoimmune Diseases 2009, 6:1 doi:10.1186/1740-2557-6-1 Authors: Paúl Alejandro Méndez Patarroyo1, José Félix Restrepo2, Samanda Adriana Rojas1, Federico Rondón3, Eric L Matteson*4 and Antonio Iglesias-Gamarra5 Introduction: Idiopathic systemic vasculitis represents a group of clinical entities having nonspecific etiology with the common characteristic of acute or chronic inflammatory compromise of the small [...]

Antiphospholipid (Hughes) syndrome: beyond pregnancy morbidity and thrombosis

2016-07-13T16:29:46+00:00 2009-11-2|Categories: Arquivo|

Published: 19 May 2009 Journal of Autoimmune Diseases 2009, 6:3 doi:10.1186/1740-2557-6-3 Authors: Maria Mialdea, Shirish R Sangle and David P D'Cruz The antiphospholipid syndrome is an autoimmune disease characterised by recurrent arterial or venous thrombosis, pregnancy morbidity and the persistence of positive antiphospholipid antibodies. Many other clinical manifestations may occur including heart valve disease, livedo reticularis, thrombocytopenia and neurological manifestations [...]

Infections and vasculitis

2016-10-16T12:02:16+00:00 2009-11-2|Categories: Arquivo|

Cristina C. Belizna1, Mohamed A. Hamidou2, Hervé Levesque1, Loic Guillevin3 and Yehuda Shoenfeld4 Vasculitis may be associated with infection, immunization or anti-microbial drugs. Infections are responsible for a number of different types of vasculitis. Conversely, patients with vasculitis may develop infections, which sometimes mimic relapse. The aim of this review is to summarize the various aspects of the inter-relationship between vasculitis [...]

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)

2016-10-16T12:02:16+00:00 2009-11-2|Categories: Arquivo|

Luqmani, R., Hennell, S., Estrach, C., Basher, D., Birrell, F., Bosworth, A., Burke, F., Callaghan, C., Candal-Couto, J., Fokke, C., Goodson, N., Homer, D., Jackman, J., Jeffreson, P., Oliver, S., Reed, M., Sanz, L., Stableford, Z., Taylor, P., Todd, N., Ver artigo completo  

CE aprova dosagem semanal de Enbrel para psoríase moderada a grave

2016-10-16T12:02:16+00:00 2009-11-2|Categories: Arquivo|

A Comissão Europeia (CE) aprovou a comercialização da versão de 50 miligramas de administração semanal do fármaco Enbrel (etanercept), da Wyeth, como alternativa à actual versão de 25 miligramas, administrada duas vezes por semana, para pacientes com psoríase em placas moderada a grave. Ver artigo completo

Advances in the use of biologic agents for the treatment of systemic vasculitis

2016-07-13T16:25:33+00:00 2009-11-2|Categories: Arquivo|

[Vasculitis syndromes: Edited by Phil Seo] Chung, Sharon A; Seo, Philip. Purpose of review: Due to the well known toxicities of cyclophosphamide, substantial interest exists in finding other therapies to treat primary systemic vasculitis. Biologic agents have been proposed as an alternative to cyclophosphamide for these disorders because of their recent success in treating other rheumatic [...]

Enbrel aprovado na Europa para a psoríase infantil

2016-10-16T12:02:17+00:00 2009-11-2|Categories: Arquivo|

A Comissão Europeia (CE) aprovou a comercialização do fármaco biológico Enbrel (etanercept), da Wyeth, para o tratamento da psoríase em placas grave em crianças. Este é o primeiro medicamento aprovado para esta indicação. A aprovação desta nova indicação já era esperada, visto vir no seguimento da recomendação positiva da Agência Europeia do Medicamento (EMEA), em Novembro [...]